Breed-Relevant Conditions Tested

Kokopelli's Ohio Good Golly Miss Molly inherited one copy of a variant that we tested for, that are relevant to her breeds:

- ✓ Von Willebrand Disease Type I (VWF)
- ✓ Progressive Retinal Atrophy, prcd (PRCD Exon 1)
- ✓ Autosomal Recessive Hereditary Nephropathy, Familial Nephropathy, ARHN (COL4A4 Exon 3)
- ✓ Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Whippet and English Springer Spaniel Variant)
- ✓ GM2 Gangliosidosis (HEXB, Poodle Variant)
- ✓ Neonatal Encephalopathy with Seizures, NEWS (ATF2)
- ✓ Hereditary Sensory Autonomic Neuropathy, Acral Mutilation Syndrome, AMS (GDNF-AS)
- ✓ Osteochondrodysplasia, Skeletal Dwarfism (SLC13A1)
- ⊖ Exercise-Induced Collapse (DNM1) (One of two copies inherited)

KOKOPELLI'S GOOD GOLLY MISS MOLLY is not at risk for Exercise-Induced Collapse, EIC and this variant should not impact her health. This variant is inherited in an autosomal recessive manner, meaning that a dog needs two copies of the variant to show signs of this condition. KOKOPELLI'S GOOD GOLLY MISS MOLLY is unlikely to develop this condition due to this variant because she only has one copy of the variant.

Additional Conditions Tested

Kokopelli's Ohio Good Golly Miss Molly did not have the variants that we tested for, in the following conditions that the potential effect on dogs with your dog's breeds may not yet be known.

- ✓ MDR1 Drug Sensitivity (ABCB1)
- ✓ P2Y12 Receptor Platelet Disorder (P2Y12)
- ✓ Factor IX Deficiency, Hemophilia B (F9 Exon 7, Terrier Variant)
- ✓ Factor IX Deficiency, Hemophilia B (F9 Exon 7, Rhodesian Ridgeback Variant)
- ✓ Factor VII Deficiency (F7 Exon 5)
- ✓ Factor VIII Deficiency, Hemophilia A (F8 Exon 10, Boxer Variant)
- ✓ Factor VIII Deficiency, Hemophilia A (F8 Exon 11, Shepherd Variant 1)
- ✓ Factor VIII Deficiency, Hemophilia A (F8 Exon 1, Shepherd Variant 2)
- ✓ Thrombopathia (RASGRP1 Exon 5, Basset Hound Variant)
- ✓ Thrombopathia (RASGRP1 Exon 8)
- ✓ Thrombopathia (RASGRP1 Exon 5, American Eskimo Dog Variant)
- ✓ Von Willebrand Disease Type III, Type III vWD (VWF Exon 4)
- ✓ Von Willebrand Disease Type III, Type III vWD (VWF Exon 7)
- ✓ Von Willebrand Disease Type II, Type II vWD (VWF)

Additional Conditions Tested

- Progressive Retinal Atrophy, crd1 (PDE6B)
- Progressive Retinal Atrophy - crd4/cord1 (RPGRIP1)
- X-Linked Progressive Retinal Atrophy 1, XL-PRA1 (RPGR)
- Progressive Retinal Atrophy, PRA3 (FAM161A)
- Collie Eye Anomaly, Choroidal Hypoplasia, CEA (NHEJ1)
- Day blindness, Cone Degeneration, Achromatopsia (CNGB3 Exon 6)
- Achromatopsia (CNGA3 Exon 7 German Shepherd Variant)
- Achromatopsia (CNGA3 Exon 7 Labrador Retriever Variant)
- Autosomal Dominant Progressive Retinal Atrophy (RHO)
- Canine Multifocal Retinopathy (BEST1 Exon 2)
- Canine Multifocal Retinopathy (BEST1 Exon 5)
- Canine Multifocal Retinopathy (BEST1 Exon 10 Deletion)
- Glaucoma (ADAMTS10 Exon 9)
- Glaucoma (ADAMTS10 Exon 17)
- Glaucoma (ADAMTS17 Exon 11)
- Glaucoma (ADAMTS17 Exon 2)
- Goniodysgenesis and Glaucoma (OLFM3)
- Hereditary Cataracts, Early-Onset Cataracts, Juvenile Cataracts (HSF4 Exon 9 Shepherd Variant)
- Primary Lens Luxation (ADAMTS17)
- Congenital Stationary Night Blindness (RPE65)
- Congenital Stationary Night Blindness (LRIT3)
- Macular Corneal Dystrophy, MCD (CHST6)
- 2,8-Dihydroxyadenine Urolithiasis, 2,8-DHA Urolithiasis (APRT)
- Cystinuria Type I-A (SLC3A1)
- Cystinuria Type II-A (SLC3A1)
- Cystinuria Type II-B (SLC7A9)
- Hyperuricosuria and Hyperuricemia or Urolithiasis, HUU (SLC2A9)
- Polycystic Kidney Disease, PKD (PKD1)
- Primary Hyperoxaluria (AGXT)
- Protein Losing Nephropathy, PLN (NPHS1)
- X-Linked Hereditary Nephropathy, XLHN (COL4A5 Exon 35, Samoyed Variant 2)
- Primary Ciliary Dyskinesia, PCD (CCDC39 Exon 3)
- Primary Ciliary Dyskinesia, PCD (NME5)
- Congenital Keratoconjunctivitis Sicca and Ichthyosiform Dermatosis, Dry Eye Curly Coat

Additional Conditions Tested

- Syndrome, CKCSID (FAM83H Exon 5)
- X-linked Ectodermal Dysplasia, Anhidrotic Ectodermal Dysplasia (EDA Intron 8)
- Renal Cystadenocarcinoma and Nodular Dermatofibrosis, RCND (FLCN Exon 7)
- Canine Fucosidosis (FUCA1)
- Glycogen Storage Disease Type II, Pompe's Disease, GSD II (GAA)
- Glycogen Storage Disease Type IA, Von Gierke Disease, GSD IA (G6PC)
- Glycogen Storage Disease Type IIIA, GSD IIIA (AGL)
- Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 1)
- Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 2)
- Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 5)
- Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 3)
- Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Wachtelhund Variant)
- Lagotto Storage Disease (ATG4D)
- Neuronal Ceroid Lipofuscinosis 1, NCL 1 (PPT1 Exon 8)
- Neuronal Ceroid Lipofuscinosis 2, NCL 2 (TPP1 Exon 4)
- Neuronal Ceroid Lipofuscinosis 1, Cerebellar Ataxia, NCL4A (ARSG Exon 2)
- Neuronal Ceroid Lipofuscinosis 1, NCL 5 (CLN5 Border Collie Variant)
- Neuronal Ceroid Lipofuscinosis 6, NCL 6 (CLN6 Exon 7)
- Neuronal Ceroid Lipofuscinosis 8, NCL 8 (CLN8 English Setter Variant)
- Neuronal Ceroid Lipofuscinosis (MFSD8)
- Neuronal Ceroid Lipofuscinosis (CLN8 Australian Shepherd Variant)
- Neuronal Ceroid Lipofuscinosis 10, NCL 10 (CTSD Exon 5)
- Neuronal Ceroid Lipofuscinosis (CLN5 Golden Retriever Variant)
- Adult-Onset Neuronal Ceroid Lipofuscinosis (ATP13A2, Tibetan Terrier Variant)
- Late-Onset Neuronal Ceroid Lipofuscinosis (ATP13A2, Australian Cattle Dog Variant)
- GM1 Gangliosidosis (GLB1 Exon 15 Shiba Inu Variant)
- GM1 Gangliosidosis (GLB1 Exon 15 Alaskan Husky Variant)
- GM1 Gangliosidosis (GLB1 Exon 2)
- GM2 Gangliosidosis (HEXA)
- Globoid Cell Leukodystrophy, Krabbe disease (GALC Exon 5)
- Autosomal Recessive Amelogenesis Imperfecta, Familial Enamel Hypoplasia (Italian Greyhound Variant)
- Autosomal Recessive Amelogenesis Imperfecta, Familial Enamel Hypoplasia (P. Russell Terrier Variant)
- Persistent Mullerian Duct Syndrome, PMDS (AMHR2)

Additional Conditions Tested

- Deafness and Vestibular Syndrome of Dobermans, DVDob, DINGS (MYO7A)
- Shar-Pei Autoinflammatory Disease, SPAID, Shar-Pei Fever (MTBP)
- Neonatal Interstitial Lung Disease (LAMP3)
- Alaskan Husky Encephalopathy, Subacute Necrotizing Encephalomyelopathy (SLC19A3)
- Alexander Disease (GFAP)
- Cerebellar Abiotrophy, Neonatal Cerebellar Cortical Degeneration, NCCD (SPTBN2)
- Cerebellar Ataxia, Progressive Early-Onset Cerebellar Ataxia (SEL1L)
- Cerebellar Hypoplasia (VLDLR)
- Spinocerebellar Ataxia, Late-Onset Ataxia, LoSCA (CAPN1)
- Spinocerebellar Ataxia with Myokymia and/or Seizures (KCNJ10)
- Hereditary Ataxia (RAB24)
- Benign Familial Juvenile Epilepsy, Remitting Focal Epilepsy (LGI2)
- Degenerative Myelopathy, DM (SOD1A)
- Fetal-Onset Neonatal Neuroaxonal Dystrophy (MFN2)
- Hypomyelination and Tremors (FNIP2)
- Shaking Puppy Syndrome, X-linked Generalized Tremor Syndrome (PLP)
- Neuroaxonal Dystrophy, NAD (Spanish Water Dog Variant)
- Neuroaxonal Dystrophy, NAD (Rottweiler Variant)
- L-2-Hydroxyglutaricaciduria, L2HGA (L2HGDH)
- Polyneuropathy, NDRG1 Malamute Variant (NDRG1 Exon 4)
- Narcolepsy (HCRTR2 Intron 6)
- Narcolepsy (HCRTR2 Exon 1)
- Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon 15)
- Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon 4)
- Juvenile Laryngeal Paralysis and Polyneuropathy, Polyneuropathy with Ocular Abnormalities and Neuronal Vacuolation, POANV (RAB3GAP1, Rottweiler Variant)
- Sensory Neuropathy (FAM134B)
- Juvenile-Onset Polyneuropathy, Leonberger Polyneuropathy 1, LPN1 (LPN1, ARHGEF10)
- Juvenile Myoclonic Epilepsy (DIRAS1)
- Juvenile-Onset Polyneuropathy, Leonberger Polyneuropathy 2, LPN2 (GJA9)
- Spongy Degeneration with Cerebellar Ataxia 1, SDCA1, SeSAME/EAST Syndrome (KCNJ10)
- Spongy Degeneration with Cerebellar Ataxia 2, SDCA2 (ATP1B2)
- Dilated Cardiomyopathy, DCM1 (PDK4)
- Dilated Cardiomyopathy, DCM2 (TTN)

Additional Conditions Tested

- Long QT Syndrome (KCNQ1)
- Cardiomyopathy and Juvenile Mortality (YARS2)
- Muscular Dystrophy (DMD, Cavalier King Charles Spaniel Variant 1)
- Muscular Dystrophy (DMD Golden Retriever Variant)
- Limb Girdle Muscular Dystrophy (SGCD, Boston Terrier Variant)
- Ulrich-like Congenital Muscular Dystrophy (COL6A3, Labrador Variant)
- Centronuclear Myopathy (PTPLA)
- Inherited Myopathy of Great Danes (BIN1)
- Myostatin Deficiency, Bully Whippet Syndrome (MSTN)
- Myotonia Congenita (CLCN1 Exon 7)
- Myotonia Congenita (CLCN1 Exon 23)
- Myotubular Myopathy 1, X-linked Myotubular Myopathy, XL-MTM (MTM1, Labrador Variant)
- Inflammatory Myopathy (SLC25A12)
- Hypocatalasia, Acatalasemia (CAT)
- Pyruvate Dehydrogenase Deficiency (PDP1)
- Malignant Hyperthermia (RYR1)
- Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 53)
- Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 8)
- Inherited Selected Cobalamin Malabsorption with Proteinuria (CUBN)
- Lundehund Syndrome (LEPREL1)
- Congenital Myasthenic Syndrome (CHAT)
- Congenital Myasthenic Syndrome (COLQ)
- Congenital Myasthenic Syndrome (CHRNE)
- Congenital Myasthenic Syndrome (COLQ)
- Myasthenia Gravis Like Syndrome (CHRNE)
- Episodic Falling Syndrome (BCAN)
- Paroxysmal Dyskinesia, PxD (PGIN)
- Demyelinating Polyneuropathy (SBF2/MTRM13)
- Dystrophic Epidermolysis Bullosa (COL7A1)
- Dystrophic Epidermolysis Bullosa (COL7A1)
- Ectodermal Dysplasia, Skin Fragility Syndrome (PKP1)
- Ichthyosis, Epidermolytic Hyperkeratosis (KRT10)
- Ichthyosis (PNPLA1)
- Ichthyosis (SLC27A4)

Additional Conditions Tested

- Ichthyosis (NIPAL4)
- Hereditary Footpad Hyperkeratosis (FAM83G)
- Hereditary Footpad Hyperkeratosis (DSG1)
- Hereditary Nasal Parakeratosis (SUV39H2)
- Musladin-Lueke Syndrome (ADAMTSL2)
- Oculocutaneous Albinism, OCA (Pekingese Type)
- Bald Thigh Syndrome (IGFBP5)
- Lethal Acrodermatitis (MKLN1)
- Ehlers Danlos (Doberman) (ADAMTS2)
- Cleft Lip and/or Cleft Palate (ADAMTS20)
- Hereditary Vitamin D-Resistant Rickets (VDR)
- Osteogenesis Imperfecta, Brittle Bone Disease (COL1A2)
- Osteogenesis Imperfecta, Brittle Bone Disease (SERPINH1)
- Osteogenesis Imperfecta, Brittle Bone Disease (COL1A1)
- Skeletal Dysplasia 2, SD2 (COL11A2)
- Craniomandibular Osteopathy, CMO (SLC37A2)
- Raine Syndrome, Canine Dental Hypomineralization Syndrome (FAM20C)
- Chondrodystrophy, Norwegian Elkhound and Karelian Bear Dog Variant (ITGA10)

Health Report

HEALTH REPORT

Notable result

Exercise-Induced Collapse, EIC

KOKOPELLI'S GOOD GOLLY MISS MOLLY inherited one copy of the variant we tested for Exercise-Induced Collapse, EIC

What does this result mean?

This variant should not impact Molly's health. This variant is inherited in an autosomal recessive manner, meaning that a dog needs two copies of the variant to show signs of this condition. Molly is unlikely to develop this condition due to this variant because she only has one copy of the variant.

Impact on Breeding

Your dog carries this variant and will pass it on to ~50% of her offspring. You can email breeders@embarkvet.com to discuss with a genetic counselor how the genotype results should be applied to a breeding program.

What is Exercise-Induced Collapse, EIC?

EIC has been linked to a mutation in the DNM1 gene, which codes for the protein dynamin. In the neuron, dynamin trucks neurotransmitter-filled vesicles from the cell body, where they are generated, to the dendrites. It is hypothesized in dogs affected with EIC, the mutation in DNM1 disrupts efficient neurotransmitter release, leading to a cessation in signaling and EIC.

When signs & symptoms develop in affected dogs

Signs develop in juvenile dogs, typically before 3 years of age.

How vets diagnose this condition

Genetic testing, clinical signs, and muscle biopsy can be used to diagnose this disorder.

How this condition is treated

Dogs with this condition are otherwise normal and healthy, though some severely affected dogs have died during an episode. The factors determining the severity of an episode on a given day or in a given dog is unknown.

Actions to take if your dog is affected

Minimizing or eliminating intense exercise is the best way we currently know to prevent complications from this condition